NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.
Saved in:
| Title: | NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma. |
|---|---|
| Authors: | Vegliante MC; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Mazzara S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Zaccaria GM; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Esposito F; Department of Mathematics, University of Bari Aldo Moro, Bari, Italy.; INDAM-GNCS Research Group, Rome, Italy., Melle F; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Motta G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Sapienza MR; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Opinto G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Volpe G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Bucci A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Gargano G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.; INDAM-GNCS Research Group, Rome, Italy., Enjuanes A; Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain., Tabanelli V; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Fiori S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Minoia C; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Clemente F; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Negri A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Gulino A; Cogentech srl Società Benefit, FIRC Institute of Molecular Oncology (IFOM), Milan, Italy., Morello G; Department of Health Sciences, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy., Scattone A; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Zito AF; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Tommasi S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Agostinelli C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Vitolo U; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Chiappella A; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Barbui AM; Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Derenzini E; Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy.; Department of Health Sciences, University of Milan, Milan, Italy., Zinzani PL; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Casadei B; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Rivas-Delgado A; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain., López-Guillermo A; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain., Campo E; CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona; University of Barcelona, Barcelona, Spain., Moschetta A; Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy., Guarini A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Pileri SA; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Ciavarella S; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy. |
| Source: | Hematological oncology [Hematol Oncol] 2022 Dec; Vol. 40 (5), pp. 864-875. Date of Electronic Publication: 2022 Aug 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.3050 |
